Αρχική World News A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in... World News A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer Από Ogkologos - 5 Αυγούστου, 2025 837 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Καρκίνος οισοφάγου 22 Ιανουαρίου, 2019 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... 21 Ιανουαρίου, 2025 Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy 27 Οκτωβρίου, 2020 Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer 2 Αυγούστου, 2019 Φόρτωση περισσοτέρων HOT NEWS Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress Protective HPV Vaccine-Induced Antibody Titres Can Be Detected Up To 12... Cómo prepararse para su exploración por TEP-TC Cancer Research UK reports record levels of investment in its spinouts